SLC5A2 and type 2 diabetes mellitus: Moreover, an analysis of pooled data from six clinical trials including 3801 patients with T2DM demonstrated that SGLT2 inhibition by canagliflozin for 26 weeks improved serum LFTs compared with either placebo or sitagliptin therapy in these patients (Leiter et al., 2016[50]).